PolyPid stock faces FDA decision as Q3 loss narrows

PolyPid said on Wednesday, November 11, 2026, that the U.S. Food and Drug Administration remains on track to decide on D-PLEX100 by November 28. The company made the announcement alongside results for the quarter ended September 30 in a PolyPid press release.

The FDA is conducting a Priority Review of the company's New Drug Application for D-PLEX100, a treatment intended to prevent surgical site infections in patients undergoing colorectal surgery. PolyPid said labeling discussions are underway and that scheduled FDA interactions remain aligned with the PDUFA goal date.

Commercial preparations move forward

Subject to approval, PolyPid and Azurity Pharmaceuticals are preparing for a potential U.S. commercial launch in early 2027. Azurity is building a commercial organization with access to more than 1,700 U.S. hospitals and academic centers, according to the company.

PolyPid has also submitted a New Technology Add-on Payment application to the Centers for Medicare & Medicaid Services. A decision is expected in August 2027, adding a reimbursement milestone to the company's commercialization plan.

In Europe, the company submitted its marketing authorization application for D-PLEX100 to the European Medicines Agency on September 14. The EMA later validated the application, beginning a formal review that PolyPid expects to conclude in the second half of 2027.

Quarterly loss narrows

PolyPid reported a third-quarter net loss of 5.8 million US dollars, or 0.24 US dollars per share, compared with a loss of 7.5 million US dollars, or 0.37 US dollars per share, a year earlier. Research and development expense rose to 6.5 million US dollars from 5.3 million US dollars as regulatory work and commercial preparations continued.

The company said it received a total of 30 million US dollars in upfront and near-term milestone payments from Azurity and remains eligible for more than 290 million US dollars in additional regulatory, launch and sales-based milestones. Management said available cash, expected partner proceeds and potential future payments should fund operations into 2028 under current plans.

PolyPid's focused drug-delivery model

PolyPid is an Israel-based biopharmaceutical company developing long-acting, controlled-release medicines designed to deliver therapy at the site of care. Its lead program, D-PLEX100, targets surgical-site infection prevention, while its pipeline also spans diabetic foot infections and metabolic disease. The company is a specialized developer focused on localized drug delivery rather than a broad diversified pharmaceutical portfolio.

U.S. biotechnology shares remain sensitive to regulatory decisions and clinical milestones; investors can follow the Nasdaq Composite for the broader market setting.

More news and analyses on PolyPid stock.